<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220701</url>
  </required_header>
  <id_info>
    <org_study_id>LXP-MD-34</org_study_id>
    <nct_id>NCT00220701</nct_id>
  </id_info>
  <brief_title>Escitalopram in the Treatment of Dysthymic Disorder, Double Blind</brief_title>
  <official_title>Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of
      dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.

      It is hypothesized that Escitalopram will be superior to placebo in improving depression, as
      well as psychosocial, temperamental, and cognitive functioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of
      Dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.

      Flexible dosing to a maximum of 40 mg per day will be used. It is hypothesized that
      Escitalopram will be superior to placebo in improving depression, as well as psychosocial,
      temperamental, and cognitive functioning. Blood cytokine levels will also be measured at
      weeks 0, 12, and 24 to determine their relationship to depressive symptoms and improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton-Depression Rating Scale (HDRS-24 Items)</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton-Depression Rating Scale (HDRS-24 Items)</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions - Severity (CGI-S)</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Baseline</time_frame>
    <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions - Severity (CGI-S)</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Week 12</time_frame>
    <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Dysthymic Disorder</condition>
  <arm_group>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inactive comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lexapro (escitalopram)</intervention_name>
    <description>antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>lexapro</other_name>
    <other_name>escitalopram</other_name>
    <other_name>s-citalopram</other_name>
    <other_name>d-citalopram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients 18-65 years of age.

          -  Patients with a Diagnostic and Statistical Manual, fourth edition (DSM-IV) diagnosis
             of dysthymic disorder.

          -  Subject must be considered reliable.

          -  Patients will have a total of 12 or higher on the Hamilton Depression Scale (24 items)
             at baseline.

        Exclusion Criteria:

          -  Patients with a DSM-IV diagnosis of Delirium, Dementia, and Amnestic, and other
             Cognitive Disorders.

          -  Patients who plan to produce a pregnancy within the next 6 months, or patients who are
             pregnant or nursing women.

          -  Patients who have a history of non-response to two or more sufficient trials of
             antidepressant medication (as defined in Table 1).

          -  Patients with a principal diagnosis meeting DSM-IV criteria for:

               -  Major Depressive Disorder, current

               -  Bipolar Disorder or cyclothymia .Schizophrenia, Delusional (Paranoid) Disorders
                  and Psychotic Disorders not elsewhere classified.

               -  Anorexia Nervosa or Bulimia

          -  Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence
             on any drug, including alcohol, excluding caffeine and tobacco.

          -  Patients who have taken psychotropic medication or herbal preparations with putative
             psychotropic effects within 7 days prior to Visit 2. Patients taking a monoamine
             oxidase inhibitor (a type of antidepressant) (MAOI) must have a washout period of 14
             days prior to visit 2, and patients taking fluoxetine must have a washout period of at
             least 4 weeks prior to Visit 2.

          -  Patients who would pose a serious risk for suicide during the course of the study, as
             evidenced by one of the following:

               -  Report of having a specific plan for killing themselves

               -  A score of 3 or higher on the Hamilton Depression Rating Scale item #3 as rated
                  by the treating clinician at Week 0, (indicative of active suicidal thoughts or
                  behaviors)

               -  A suicide attempt within the past 12 months requiring emergency room visit,
                  medical or psychiatric hospitalization, or otherwise deemed to be
                  life-threatening (e.g. an overdose of &gt; 1 week's dose of medication.

          -  Patients with unstable medical conditions, such as acute hyperthyroidism, uncorrected
             hypothyroidism, undiagnosed fever, uncontrolled angina, or any other serious medical
             illness, including any cardiovascular, hepatic, respiratory, hematological,
             endocrinologic o neurologic disease, or any clinically significant laboratory
             abnormality.

          -  Patients who lack the capacity to proved informed consent

          -  50% or greater decrease in HDRS total score from visit 2 to visit 3 or a
             CGI-Improvement score of 1 (&quot;very much improved&quot;) or 2 (&quot;much improved&quot;) at Visit 3

          -  Patients receiving CGI Improvement scores of 6 (&quot;much worse&quot;) or 7 (&quot;very much worse&quot;)
             for two consecutive visits will be withdrawn from the study.

          -  Patients who meet criteria for Major Depressive Disorder at any time during the course
             of the study will be withdrawn from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Hellerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital, and NY State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mood Disorders Research Program, St. Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.DepressionNY.com</url>
    <description>For more information about our program and this study click here.</description>
  </link>
  <results_reference>
    <citation>Hellerstein DJ, Batchelder ST, Hyler S, Arnaout B, Toba C, Benga I, Gangure D. Escitalopram versus placebo in the treatment of dysthymic disorder. Int Clin Psychopharmacol. 2010 May;25(3):143-8. doi: 10.1097/YIC.0b013e328333c35e.</citation>
    <PMID>21811192</PMID>
  </results_reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>November 19, 2014</results_first_submitted>
  <results_first_submitted_qc>November 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2014</results_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysthymic Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Chronic Depression</keyword>
  <keyword>Escitalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram</title>
          <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram</title>
          <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.88" spread="9.92"/>
                    <measurement group_id="B2" value="43.59" spread="11.33"/>
                    <measurement group_id="B3" value="43.74" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton-Depression Rating Scale (HDRS-24 Items)</title>
        <description>Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton-Depression Rating Scale (HDRS-24 Items)</title>
          <description>Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.88" spread="5.83"/>
                    <measurement group_id="O2" value="16.41" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Repeated Measures ANOVA</method>
            <param_type>F statistics</param_type>
            <param_value>2.82</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions - Severity (CGI-S)</title>
        <description>Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology)</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions - Severity (CGI-S)</title>
          <description>Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.93"/>
                    <measurement group_id="O2" value="3.41" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" spread="5.21"/>
                    <measurement group_id="O2" value="16.25" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hamilton-Depression Rating Scale (HDRS-24 Items)</title>
        <description>Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton-Depression Rating Scale (HDRS-24 Items)</title>
          <description>Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (&gt;50% decrease) Remission (score&lt;=7)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.82" spread="5.75"/>
                    <measurement group_id="O2" value="24.41" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions - Severity (CGI-S)</title>
        <description>Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions - Severity (CGI-S)</title>
          <description>Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="0.24"/>
                    <measurement group_id="O2" value="4.06" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" spread="4.91"/>
                    <measurement group_id="O2" value="10.00" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were evaluated weekly for the first two weeks after randomization and then biweekly thereafter till week 12.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram</title>
          <description>Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>inactive comparator
Lexapro (escitalopram): antidepressant drug selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upset stomach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Delayed Ejection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small double blinded study with limited power.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Hellerstein MD</name_or_title>
      <organization>NY State Psychiatric Institute</organization>
      <phone>6467748000</phone>
      <email>hellers@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

